An interventional study of Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks. in HIV, sponsored by Fundacion SEIMC-GESIDA. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-29.
Sponsored by Fundacion SEIMC-GESIDA · Not applicable, Interventional, and Treatment
Cidofovir could be an effective drug for the treatment of Anal Intraepithelial Neoplasia(AIN).
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 20 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Fundacion SEIMC-GESIDA is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who have given informed consent in writing of the study before making any specific selection procedure for the study.
Patients who have received previous treatment of Anal Intraepithelial Neoplasia (AIN) in the last 12 weeks. 2. Dermatoses in patients with anogenital area 3. Patients with a history of pre-invasive neoplasia associated with Human Papilloma Virus 4. Patients with a history of previous neoplasm, of any origin and location, in the past 5 years.
Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
Drug: Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
Percentage of patients with complete regression of anal intraepithelial neoplasia
Describe the percentage of patients achieving complete regression of anal intraepithelial neoplasia (AIN), as confirmed by means of high-resolution anoscopy and biopsy
Time frame: 8 Weeks
Describe the percentage of patients that reduce the degree of Anal dysplasia
Describe the percentage of patients that reduce the degree of Anal dysplasia
Time frame: 8 weeks
Describe the percentage of patients that reduces the extent Intraepithelial Anal Dysplasia quadrants, although not complete regression
Describe the percentage of patients that reduces the extent Intraepithelial Anal Dysplasia quadrants, although not complete regression
Time frame: 8 Weeks
Time to relapse
Describe the percentage of patients with recurrence after complete regression of HSIL and median time to relapse
Time frame: 8 Weeks
Percentage of patients with clear of Human papillomavirus
Describe the percentage of patients in whom Human Papillomavirus clears after treatment with cidofovir
Time frame: 8 Weeks
Percentage of adverse events
Describe the number of patients with adverse events as a measure of safety and tolerability
Time frame: 8 weeks
Treatment effect
Prospective Clinical Trial exploratory nature of the effect of treatment.
Time frame: 8 Weeks
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion SEIMC-GESIDA